Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022-2030 guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis B and C and sexually transmitted infections by 2030. The 2022-2030 strategies recommend shared and disease-specific country actions supported by actions by the World Health Organization and partners. They consider the epidemiological, technological, and contextual shifts of recent years, foster learnings across the disease areas, and create opportunities to leverage innovations and new knowledge for effective responses to HIV, viral hepatitis, and sexually transmitted infections.

The strategies call for a precise focus to reach the people most affected and at risk for each disease that addresses inequities. They promote synergies under a universal health coverage and primary health care framework and contribute to achieving the goals of the 2030 Agenda for Sustainable Development. The Seventy-Fifth World Health Assembly requested progress reports on the implementation of the strategies in 2024, 2026, 2028 and 2031, noting that the 2026 report will provide a mid-term review based on the progress made in meeting the strategies’ 2025 targets.

P.37 Action 2: Harm reduction and treatment interventions for people who inject drugs.
Implement a comprehensive package of accessible harm reduction and treatment services, where appropriate, as part of a comprehensive package of interventions for the prevention, treatment, and care of HIV among people who inject drugs27,28 and for people who use stimuant drugs29, in line with the domestic context, legislation and jurisdictional responsibilities. The essential package of harm reduction services for people who inject drugs includes the provision of sterile injecting equipment through needle and syringe programmes, opioid agonist maintenance therapy for people dependent on opioids, and the community distribution of opioid antagonist medication for the management of opioid overdose, along with targeted information and communication, and testing, diagnosis and management of HIV, hepatitis B and C virus, sexually transmitted infections and related infections. Interventions tailored to the needs of people who use or inject drugs such as amphetamine-type stimulants, and to address other forms of sexualized drug use among some key populations, are also important, as well as offering appropriate treatment including evidence-based psychosocial interventions that are effective in reducing drug use, promoting abstinence and preventing relapse. Harm reduction is most effective when it is rolled out in the context of broader prevention and treatment efforts, and a combination of harm reduction interventions with high coverage levels is needed for maximum impact. Harm reduction should be made available as part of a comprehensive prevention, treatment and care approach for people who use drugs, which includes different forms of drug treatment including for people seeking to stop their drug use...